Nanomedical Diagnostics, a Serra Capital II portfolio company, has announced a breakthrough study published in the Journal of the American Chemical Society on June 20. Nanomedical Diagnostics is a biotech company developing and commercializing graphene biosensors for use in life science research and diagnostics.
The company's novel AGILE Graphene Biosensor has been found to advance kinase research for the development of therapeutic pharmaceuticals, demonstrating previously unattainable measurements for kinase drug discovery. Dr. Nir Qvit, lead author of the study, said “AGILE performed splendidly, and the data was quantitative and reproducible. The technology is one-of-a-kind.”